PUBLISHER: BCC Research | PRODUCT CODE: 1057101
PUBLISHER: BCC Research | PRODUCT CODE: 1057101
The global market for circulating tumor cells (CTC) diagnostics is estimated to increase from $8.8 billion in 2021 to $15.2 billion by 2026, at a compound annual growth rate (CAGR) of 15.6% during the forecast period of 2021-2026.
The global market for breast cancer diagnostics is estimated to increase from $3.6 billion in 2021 to $7.3 billion by 2026, at a CAGR of 15.3% during the forecast period of 2021-2026.
The global market for colorectal cancer diagnostics is estimated to increase from $2.9 billion in 2021 to $6.0 billion by 2026, at a CAGR of 16.0% during the forecast period of 2021-2026.
The scope of this study involves clinical testing, prognostic and monitoring markets for CTCs in cancer. The report also includes the clinical research segment as well as currently approved CTC tests and their markets. The regulatory environment, current technologies, new technologies, cancer incidence, market projections and market share, along with the latest trends and new developments in this area, are included to support the clinical testing market.
Based on cancer type, the market for circulating tumor cells diagnostics is segmented into breast cancer, colorectal cancer and prostate cancer.
Based on technology, the market for circulating tumor cells diagnostics is segmented into CTC enrichment and detection, CTC direct detection and CTC analysis.
Based on application, the market for circulating tumor cells diagnostics is segmented into clinical/liquid biopsy and research.
The report discusses the qualitative and quantitative factors influencing market growth. Market drivers, restraints and opportunities are discussed in the report.
This report discusses some of the major drivers and restraints in the market for circulating tumor cells diagnostics, and it surveys the competitive landscape as well as the key players' strategies and performances. The discussion is focused on the major market players, trends in product launches, collaborations, and mergers and acquisitions. The report also includes company profiles of major vendors that include a company overview, key product offerings, financial statistics and recent developments. The report provides insights on market shares and upcoming regional demand for circulating tumor cells diagnostics.
Some of the major market players discussed in the report are Qiagen N.V., Biocept Inc., Greiner Bio One International GmbH, Precision Medicine Group LLC and Menarini Silicon Biosystems. For market estimates, data have been provided for the 2020 as the base year, with forecasts for 2021 through 2026. Projected and forecasted revenue values are in constant U.S. dollars that have not been adjusted for inflation.
Table A : New Additions to the Updated Version of the Report